Bio-Rad Labs (BIO) Tops Q3 EPS by 31c, provides outlook

Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $2.26, $0.31 better than the analyst estimate of $1.95. Revenue for the quarter came in at $653 million versus the consensus estimate of $652.24 million.

Full-Year 2025 Financial Outlook

Bio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)